Zhuhai Lichen Biotech

Lichen Biotech is a clinical-stage biopharmaceutical company headquartered in Zhuhai, China, dedicated to the discovery and development of novel small molecule drugs for metabolic disorders. The company's primary focus is on addressing the global burden of gout and hyperuricemia through the inhibition of key transporters involved in uric acid regulation. Its lead clinical asset, LC-2860, is a highly selective Urate anion exchanger 1 (URAT1) inhibitor that has demonstrated promising efficacy and safety profiles in early clinical studies. Beyond its lead program, Lichen Biotech is building a pipeline of candidates targeting various metabolic pathways to improve patient outcomes in chronic disease management. The company has successfully secured significant financing from leading life science investors to accelerate its clinical programs toward commercialization. Its research and development efforts leverage deep expertise in medicinal chemistry to optimize small molecule inhibitors for metabolic targets.